146 related articles for article (PubMed ID: 9871571)
1. A novel series of N-(hexahydro-1,4-diazepin-6-yl) and N-(hexahydroazepin- 3-yl)benzamides with high affinity for 5-HT3 and dopamine D2 receptors.
Hirokawa Y; Morie T; Yamazaki H; Yoshida N; Kato S
Bioorg Med Chem Lett; 1998 Mar; 8(6):619-24. PubMed ID: 9871571
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationships of 4-amino-5-chloro-N-(1,4-dialkylhexahydro-1,4-diazepin-6-yl)-2-methoxybenzamide derivatives, novel and potent serotonin 5-HT3 and dopamine D2 receptors dual antagonist.
Hirokawa Y; Harada H; Yoshikawa T; Yoshida N; Kato S
Chem Pharm Bull (Tokyo); 2002 Jul; 50(7):941-59. PubMed ID: 12130853
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)nicotinamides and their affinities for 5-HT3 and dopamine D2 receptors.
Hirokawa Y; Yoshida N; Kato S
Bioorg Med Chem Lett; 1998 Jun; 8(12):1551-4. PubMed ID: 9873388
[TBL] [Abstract][Full Text] [Related]
5. New benzamide-derived 5-HT3 receptor antagonists which prevent the effects of ethanol on extracellular dopamine, and fail to reduce voluntary alcohol intake in rats.
Iusco G; Boido V; Sparatore F; Colombo G; Saba PL; Rossetti Z; Vaccari A
Farmaco; 1997 Mar; 52(3):141-6. PubMed ID: 9212448
[TBL] [Abstract][Full Text] [Related]
6. The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.
Yoshikawa T; Yoshida N; Oka M
Br J Pharmacol; 2001 May; 133(2):253-60. PubMed ID: 11350861
[TBL] [Abstract][Full Text] [Related]
7. Nitrogen-containing heteroalicycles with serotonin receptor binding affinity: development of gastroprokinetic and antiemetic agents.
Kato S; Fujiwara I; Yoshida N
Med Res Rev; 1999 Jan; 19(1):25-73. PubMed ID: 9918193
[TBL] [Abstract][Full Text] [Related]
8. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro.
Wong EH; Clark R; Leung E; Loury D; Bonhaus DW; Jakeman L; Parnes H; Whiting RL; Eglen RM
Br J Pharmacol; 1995 Feb; 114(4):851-9. PubMed ID: 7773546
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of 5-HT3 binding sites in NG108-15, NCB-20 neuroblastoma cells and rat cerebral cortex using [3H]-quipazine and [3H]-GR65630 binding.
Sharif NA; Wong EH; Loury DN; Stefanich E; Michel AD; Eglen RM; Whiting RL
Br J Pharmacol; 1991 Apr; 102(4):919-25. PubMed ID: 1830236
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of the non-5-HT3 high-affinity 'R' binding site for (R)-zacopride in brain and other tissues.
Kidd FJ; Levy JC; Nielsen M; Hamon M; Gozlan H
Eur J Pharmacol; 1993 Sep; 247(1):45-56. PubMed ID: 8258360
[TBL] [Abstract][Full Text] [Related]
11. Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: evidence for identical binding sites.
Malmberg A; Jerning E; Mohell N
Eur J Pharmacol; 1996 May; 303(1-2):123-8. PubMed ID: 8804920
[TBL] [Abstract][Full Text] [Related]
12. Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annelated indole derivatives.
van Wijngaarden I; Hamminga D; van Hes R; Standaar PJ; Tipker J; Tulp MT; Mol F; Olivier B; de Jonge A
J Med Chem; 1993 Nov; 36(23):3693-9. PubMed ID: 8246239
[TBL] [Abstract][Full Text] [Related]
13. High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors.
Kessler RM; Ansari MS; Schmidt DE; de Paulis T; Clanton JA; Innis R; al-Tikriti M; Manning RG; Gillespie D
Life Sci; 1991; 49(8):617-28. PubMed ID: 1830917
[TBL] [Abstract][Full Text] [Related]
14. Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
Youssefyeh RD; Campbell HF; Klein S; Airey JE; Darkes P; Powers M; Schnapper M; Neuenschwander K; Fitzpatrick LR; Pendley CE
J Med Chem; 1992 Mar; 35(5):895-903. PubMed ID: 1312602
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of 5-HT3 receptor function by imidazolines in mouse neuroblastoma cells: potential involvement of sigma 2 binding sites.
Molderings GJ; Schmidt K; Bönisch H; Göthert M
Naunyn Schmiedebergs Arch Pharmacol; 1996; 354(3):245-52. PubMed ID: 8878053
[TBL] [Abstract][Full Text] [Related]
16. Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding.
Heidempergher F; Pillan A; Pinciroli V; Vaghi F; Arrigoni C; Bolis G; Caccia C; Dho L; McArthur R; Varasi M
J Med Chem; 1997 Oct; 40(21):3369-80. PubMed ID: 9341912
[TBL] [Abstract][Full Text] [Related]
17. New hexahydrocarbazoles and spiro indoles, and their affinity for D2 dopamine and 5-HT2A serotonin receptors.
Fernández F; García-Mera X; Rodríguez G; Urrutia A
Chem Pharm Bull (Tokyo); 1999 Jul; 47(7):1006-9. PubMed ID: 10434402
[TBL] [Abstract][Full Text] [Related]
18. 1-[omega-(4-arylpiperazin-1-yl)alkyl]-3-diphenylmethylene-2,5- pyrrolidinediones as 5-HT1A receptor ligands: study of the steric requirements of the terminal amide fragment on 5-HT1A affinity/selectivity.
López-Rodríguez ML; Morcillo MJ; Rovat TK; Fernández E; Sanz AM; Orensanz L
Bioorg Med Chem Lett; 1998 Mar; 8(6):581-6. PubMed ID: 9871564
[TBL] [Abstract][Full Text] [Related]
19. Cyclic benzamides as mixed dopamine D2/serotonin 5-HT2 receptor antagonists: potential atypical antipsychotic agents.
Norman MH; Rigdon GC; Navas F; Cooper BR
J Med Chem; 1994 Aug; 37(16):2552-63. PubMed ID: 7914539
[TBL] [Abstract][Full Text] [Related]
20. Dopamine D4-like binding sites labeled by [3H]nemonapride include substantial serotonin 5-HT2A receptors in primate cerebral cortex.
Noda-Saita K; Matsumoto M; Hidaka K; Hatanaka K; Ohmori J; Okada M; Yamaguchi T
Biochem Biophys Res Commun; 1999 Feb; 255(2):367-70. PubMed ID: 10049714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
